New 'Double-Target' cell therapy tested for tough blood cancers
NCT ID NCT04007029
Summary
This early-stage study is testing the safety and best dose of a new type of CAR-T cell therapy for patients with B-cell lymphomas or chronic lymphocytic leukemia that has come back or hasn't responded to other treatments. Doctors take a patient's own immune cells, modify them in a lab to recognize two cancer markers (CD19 and CD20), and infuse them back after a short course of chemotherapy. The main goal is to see how safe this combined approach is and if it helps control these aggressive cancers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, 90095, United States
Conditions
Explore the condition pages connected to this study.